Source-grounded facts extracted from Atea Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Atea Pharmaceuticals, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.
“Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 47,452,759 2,977,290 643,628 8,669,142”
Atea Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-18 meeting.
“Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTE 58,894,207 783,081 65,531 0”
Atea Pharmaceuticals, Inc. shareholders approved Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. at the 2026-06-18 meeting.
“Proposal 1 — Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. FOR WITHHOLD BROKER NON-VOTE Jerome Adams, MD, MPH 28,798,012 22,275,665 8,669,142 Howard Berman, PhD 44,466,627 6,607,050 8,669,142 Barbara Duncan 43,697,098 7,376,579 8,669,142”
Atea Pharmaceuticals, Inc. reported financial results for for the first quarter ended March 31, 2026.
“On May 12, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026”
Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.”
Franklin Berger departed as Class I director at Atea Pharmaceuticals, Inc..
“In addition, on April 16, 2025, in connection with the Agreement, Franklin Berger informed the Board that he would retire following the end of his current term as a Class I director at the 2027 Annual Meeting.”
Howard H. Berman was appointed as Class III director at Atea Pharmaceuticals, Inc..
“On April 16, 2025, the Board appointed Howard H. Berman, Ph.D. as a Class III director of the Company, effective at the Effective Time.”
Arthur Kirsch was elected as Class I director at Atea Pharmaceuticals, Inc..
“On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.”
Atea Pharmaceuticals, Inc. reported financial results for three months ended March 31, 2024.
“On May 14, 2024, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024”
Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.”
Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2023.
“Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023”
Atea Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended June 30, 2023 and other matters described in the press release.”
Atea Pharmaceuticals, Inc.: Amended restated bylaws to address universal proxy rules, enhance stockholder nomination and proposal disclosure requirements, and require non-white proxy card color for stockholder solicitations (effective 2023-06-16).
“On June 16, 2023, the Board of Directors (“Board”) of Atea Pharmaceuticals, Inc. (the “Company”) amended the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day. Among other things, the Amended and Restated Bylaws: • address the universal proxy rules adopted by the U.S. Securities and Exchange Commission (the “SEC”), by clarifying that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including applicable notice and solicitation requirements; • enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company’s proxy materials pursuant to Rule 14a-8 under Exchange Act), inclu”
Atea Pharmaceuticals, Inc. shareholders approved Advisory (non-binding) approval of the compensation of the Company’s named executive officers at the 2022-06-16 meeting.
“Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,032,147 15,511,146 1,437,152 13,840,079”
Atea Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2022-06-16 meeting.
“Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 64,494,470 6,285,533 40,521 0”
Atea Pharmaceuticals, Inc. shareholders approved Election of two Class III Directors to serve until the 2026 Annual Meeting of Stockholders at the 2022-06-16 meeting.
“Item 1 — Election of two Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Jerome Adams, M.D. 34,544,693 22,435,752 13,840,079 Barbara Duncan 40,592,669 16,387,776 13,840,079”
Atea Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2023.
“On May 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2023 and other matters described in the press release.”
Atea Pharmaceuticals, Inc. reported financial results for Q4 and Full Year 2022.
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.”
Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.